Biologics Control Act of 1972
GPTKB entity
Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:legislation
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Biologics_Control_Act
|
| gptkbp:addresses |
adverse event reporting
labeling requirements manufacturing standards |
| gptkbp:aims_to |
public health
|
| gptkbp:amended_by |
gptkb:Public_Health_Service_Act
|
| gptkbp:applies_to |
vaccines
blood products cellular therapies gene therapies |
| gptkbp:effective_date |
1972-09-01
|
| gptkbp:enacted_by |
gptkb:legislation
|
| gptkbp:established |
licensing requirements
inspections of facilities |
| gptkbp:governed_by |
gptkb:Food_and_Drug_Administration
|
| gptkbp:has_impact_on |
gptkb:legislation
public trust in vaccines biologics market |
| https://www.w3.org/2000/01/rdf-schema#label |
Biologics Control Act of 1972
|
| gptkbp:influenced_by |
gptkb:historical_event
public health concerns |
| gptkbp:is_cited_in |
gptkb:academic_research
gptkb:legal_case healthcare regulations policy discussions legislative history |
| gptkbp:is_part_of |
U. S. health law
|
| gptkbp:is_related_to |
gptkb:legislation
gptkb:healthcare_access gptkb:Company patient safety FDA regulations patient advocacy public health initiatives drug approval process vaccine development healthcare quality assurance healthcare economics biomedical innovation regulatory science public health law global health policy clinical research ethics biologics manufacturing |
| gptkbp:part_of |
biologics regulation framework
|
| gptkbp:promotes |
research and development
|
| gptkbp:regulates |
gptkb:Company
|
| gptkbp:related_to |
gptkb:Company
pharmaceutical regulation |
| gptkbp:replaced_by |
subsequent legislation
|
| gptkbp:requires |
clinical trials
safety testing efficacy testing |
| gptkbp:signed_by |
gptkb:Henry_Nixon
|